Patents by Inventor Che-Leung Law

Che-Leung Law has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240131176
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Application
    Filed: February 9, 2023
    Publication date: April 25, 2024
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Publication number: 20240123061
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Application
    Filed: December 8, 2023
    Publication date: April 18, 2024
    Inventors: Edward A. CLARK, Deborah L. FULLER, Che-Leung LAW, Amanda MAK
  • Publication number: 20240084035
    Abstract: Provided herein are combinations or compositions comprising immunomodulators and immune cell engaging proteins. Also provided herein are methods of use thereof, such as methods of treatment by administering the combinations or compositions comprising immunomodulators and immune cell engaging proteins to a subject. The method may be used to treat a cancer in the subject.
    Type: Application
    Filed: August 28, 2023
    Publication date: March 14, 2024
    Inventors: Mary Ellen MOLLOY, Che-Leung LAW, Richard J. AUSTIN, Bryan D. LEMON, Holger WESCHE, Wade H. AARON
  • Publication number: 20240075135
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Application
    Filed: September 20, 2023
    Publication date: March 7, 2024
    Inventors: Shyra Gardai, Che-Leung Law, Stanford Peng, Jing Yang, Haley Neff-LaFord, Thomas John Manley
  • Publication number: 20240075134
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Application
    Filed: September 20, 2023
    Publication date: March 7, 2024
    Inventors: Shyra Gardai, Che-Leung Law, Stanford Peng, Jing Yang, Haley Neff-LaFord
  • Patent number: 11883488
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: January 30, 2024
    Assignee: Abacus Bioscience, Inc.
    Inventors: Edward A. Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak
  • Publication number: 20230218776
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
    Type: Application
    Filed: November 23, 2022
    Publication date: July 13, 2023
    Applicant: SEAGEN INC.
    Inventors: Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
  • Publication number: 20230201343
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Application
    Filed: November 2, 2022
    Publication date: June 29, 2023
    Inventors: Shyra Gardai, Che-Leung Law, Stanford Peng, Jing Yang, Haley Neff-LaFord, Thomas John Manley
  • Publication number: 20230201344
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Application
    Filed: November 9, 2022
    Publication date: June 29, 2023
    Inventors: Shyra Gardai, Che-Leung LAW, Stanford Peng, Jing Yang, Haley Neff-LaFord
  • Publication number: 20230105802
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.
    Type: Application
    Filed: August 15, 2022
    Publication date: April 6, 2023
    Applicant: Seagen Inc.
    Inventors: Timothy S. Lewis, Che-Leung Law
  • Patent number: 11607460
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: March 21, 2023
    Assignee: SEAGEN INC.
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Publication number: 20230053634
    Abstract: Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpre S1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.
    Type: Application
    Filed: July 1, 2022
    Publication date: February 23, 2023
    Inventors: Edward A. CLARK, Che-Leung LAW, Deborah FULLER, Michael GALE
  • Publication number: 20220265822
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Application
    Filed: May 2, 2022
    Publication date: August 25, 2022
    Inventors: Shyra Gardai, Che-Leung LAW, Stanford Peng, Jing Yang, Haley Neff-LaFord
  • Publication number: 20220249662
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 11, 2022
    Inventors: Shyra Gardai, Che-Leung Law, Stanford Peng, Jing Yang, Haley Neff-LaFord, Thomas John Manley
  • Publication number: 20220241403
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 4, 2022
    Inventors: Edward A. CLARK, Deborah L. FULLER, Che-Leung LAW, Amanda MAK
  • Patent number: 11389532
    Abstract: Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: July 19, 2022
    Assignees: University of Washington, Abacus Bioscience, Inc.
    Inventors: Edward A. Clark, Che-Leung Law, Deborah Fuller, Michael Gale
  • Patent number: 11351269
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 7, 2022
    Assignee: Seagen Inc.
    Inventors: Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
  • Patent number: 11324819
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: May 10, 2022
    Assignees: University of Washington, Abacus Bioscience, Inc.
    Inventors: Edward Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak
  • Publication number: 20220135674
    Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Applicant: Seagen Inc.
    Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
  • Patent number: 11213584
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: January 4, 2022
    Assignee: Seagen Inc.
    Inventors: Shyra Gardai, Che-Leung Law, Stanford Peng, Jing Yang, Haley Neff-LaFord